These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32382537)

  • 1. Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV.
    Li F; Ma A; Zhao B
    Biomed Res Int; 2020; 2020():2428348. PubMed ID: 32382537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Huang Z; Ding Q; Yan M; Lian H; Chen Z; Chen X; Song Y
    Retina; 2019 May; 39(5):889-895. PubMed ID: 29360683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
    BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy.
    Peng Y; Zhang X; Li M; Liu B; Mi L; Zuo C; Wen F
    Drug Des Devel Ther; 2018; 12():339-345. PubMed ID: 29497280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
    JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
    Takayama K; Kaneko H; Kataoka K; Ueno S; Chang-Hua P; Ito Y; Terasaki H
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):449-455. PubMed ID: 27538907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
    Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
    Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
    Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
    Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sagong M; Lim S; Chang W
    Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypoidal choroidal vasculopathy treatment options: A meta-analysis.
    Qian T; Li X; Zhao M; Xu X
    Eur J Clin Invest; 2018 Jan; 48(1):. PubMed ID: 28981139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
    Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy.
    Ye LH; Cai Y; Shi X; Wong IYH; Qu JF; Zhao MW; Ying X; Li XX
    Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1455-1462. PubMed ID: 33146832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S; Matsumiya W; Keiko O; Miki A; Nakamura M; Honda S
    Jpn J Ophthalmol; 2019 Jan; 63(1):100-108. PubMed ID: 30406511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.